Literature DB >> 32182543

The internet market for Kratom, an opioid alternative and variably legal recreational drug.

Rebecca S Williams1, Dmitriy Nikitin2.   

Abstract

BACKGROUND: Amidst the opioid crisis, many people are turning to plant-based kratom for self-treatment of pain, opioid addiction, and for recreational use. Its legality is variable and its safety and medicinal effects are not agreed upon. It is broadly available from Internet Kratom Vendors (IKVs).
METHODS: An examination of the online marketplace for kratom was conducted to provide context to the market amidst regulatory attempts by the Food and Drug Administration (FDA) and state legislatures. A complex search strategy identified 663 English-language IKVs selling kratom for home delivery. The 100 most popular were selected for in-depth content analysis. IKVs were visited once for content analysis data collection in December, 2017 and revisited in April 2018 to assess responses to FDA action. IKV website and social media profiles were coded for topics including location, payment and shipping options, age verification, health warnings and disclaimers, and grassroots advocacy regarding upcoming state/federal regulations.
RESULTS: Forty-seven percent of IKVs claimed that kratom provides pain relief, 25% claimed it provides relief from opioid withdrawal, 81% featured a disclaimer that kratom is addictive, 54% stated that kratom is not FDA approved, and 66% featured disclaimers that it was not intended for consumption. Only 5% of vendors advertised effective age verification (such as verifying age at delivery). Compliance on the vendor's part with state and local bans varied by ban location, with only 27% prohibiting sales to Rhode Island while 65% did not ship to Indiana.
CONCLUSIONS: IKVs provide easy access to a wide variety of unregulated intoxicating products with poor age verification and low adherence to US state- and local-level restrictions. There is a high prevalence of vendors featuring health claims forbidden by the Food and Drug Administration. Lessons learned from regulating the Internet cigarette sales industry could be effectively applied to IKVs with future efforts.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Addiction; Age verification; Food and Drug Administration; Internet sales; Kratom; Opioid

Mesh:

Substances:

Year:  2020        PMID: 32182543     DOI: 10.1016/j.drugpo.2020.102715

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  5 in total

1.  Associations of Lifetime Nonmedical Opioid, Methamphetamine, and Kratom Use within a Nationally Representative US Sample.

Authors:  Kirsten E Smith; Jeffrey M Rogers; Justin C Strickland
Journal:  J Psychoactive Drugs       Date:  2021-11-29

2.  Kratom Use Among U.S. Adolescents: Analyses of the 2019 National Survey on Drug Use and Health.

Authors:  Vinita Sharma; Linda B Cottler; Cristina B Bares; Catalina Lopez-Quintero
Journal:  J Adolesc Health       Date:  2021-11-23       Impact factor: 7.830

Review 3.  Mitragyna Species as Pharmacological Agents: From Abuse to Promising Pharmaceutical Products.

Authors:  Islamudin Ahmad; Wisnu Cahyo Prabowo; Muhammad Arifuddin; Jaka Fadraersada; Niken Indriyanti; Herman Herman; Reza Yuridian Purwoko; Firzan Nainu; Anton Rahmadi; Swandari Paramita; Hadi Kuncoro; Nur Mita; Angga Cipta Narsa; Fajar Prasetya; Arsyik Ibrahim; Laode Rijai; Gemini Alam; Abdul Mun'im; Sukanya Dej-Adisai
Journal:  Life (Basel)       Date:  2022-01-27

4.  For Better or Worse: Self-reported Changes in Kratom and Other Substance Use as a Result of the COVID-19 Pandemic.

Authors:  Jeffrey M Rogers; Kirsten E Smith; Destiny Schriefer; David H Epstein
Journal:  Subst Abuse       Date:  2022-09-28

5.  Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations.

Authors:  Rakshit S Tanna; Dan-Dan Tian; Nadja B Cech; Nicholas H Oberlies; Allan E Rettie; Kenneth E Thummel; Mary F Paine
Journal:  J Pharmacol Exp Ther       Date:  2020-10-22       Impact factor: 4.030

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.